BloggingStocks http://www.bloggingstocks.com BloggingStocks http://www.blogsmithmedia.com/http://www.bloggingstocks.com/media/feedlogo.gif BloggingStocks http://www.bloggingstocks.com en-us Copyright 2012 Weblogs, Inc. The contents of this feed are available for non-commercial use only. Blogsmith http://www.blogsmith.com/<![CDATA[Pfizer reports solid quarterly earnings thanks to cost-cutting maneuvers]]>http://www.bloggingstocks.com/2009/10/20/pfizer-reports-solid-quarterly-earnings-thanks-to-cost-cutting-m/http://www.bloggingstocks.com/2009/10/20/pfizer-reports-solid-quarterly-earnings-thanks-to-cost-cutting-m/http://www.bloggingstocks.com/2009/10/20/pfizer-reports-solid-quarterly-earnings-thanks-to-cost-cutting-m/#commentsFiled under: ,

On Tuesday, Pfizer (NYSE: PFE) stepped into the earnings spotlight, announcing a higher third-quarter profit compared to last year. The pharmaceutical firm earned 43 cents per share, or 51 cents per share in adjusted earnings. A year ago, PFE earned 34 cents per share before item exclusions. The Street expected PFE to report third-quarter earnings of 48 cents per share excluding items.

Quarterly revenue checked in at $11.62 billion, 3% lower than last year's third-quarter revenue. Revenue was pulled roughly 5% lower due to unfavorable foreign exchange rates.

Continue reading Pfizer reports solid quarterly earnings thanks to cost-cutting maneuvers

Pfizer reports solid quarterly earnings thanks to cost-cutting maneuvers originally appeared on BloggingStocks on Tue, 20 Oct 2009 09:30:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>featuredintegrationjob lossesJobLossesjobsmedicinepfePfizerpharmaceutical sectorpharmaceuticalsPharmaceuticalSectorWyethTue, 20 Oct 2009 09:30:00 EST<![CDATA[Is this the best time to commit new money to stocks?]]>http://www.bloggingstocks.com/2008/12/03/is-this-the-best-time-to-commit-new-money-to-stocks/http://www.bloggingstocks.com/2008/12/03/is-this-the-best-time-to-commit-new-money-to-stocks/http://www.bloggingstocks.com/2008/12/03/is-this-the-best-time-to-commit-new-money-to-stocks/#commentsFiled under: , , ,

What's one reason for not jumping back in the market at this juncture?

Well, one could certainly cite end-of-the-year tax loss selling, which typically weighs on the market. Or the battle for Dow 8,000 between institutional bulls and bears. Or the fact that the Dow's path of least resistance, from a technical standpoint, remains down. (That's a major reason why the Dow drops so quickly: all that's required is a hedge fund manager to sneeze and the Dow drops 300 points, or so it seems.)

All of the above are valid reasons to remain on the sidelines.

Is Washington planning big changes?

But perhaps the best reason to not deploy new capital is the new era itself. The United States is preparing for a new presidential administration and one gets the sense that there could be a series of seismic shifts up ahead -- shifts that will affect money, markets, investing, and business trends.

It's true that after the U.S. government's allocation, via loans, loan guarantees, or investments, of about $8.2 trillion for the financial system, it's hard to picture shifts up ahead that could be as landscape-altering as those undertaken in the past year. But that could very well be the case nevertheless.

Those hoping for small change are likely to be disappointed. On January 20, President-elect Obama becomes President Obama and he is big change. U.S. Senator and now Secretary of State-designate Hillary Clinton, D-New York, was small change, and we saw how the electorate responded to her candidacy. Voters were so adamant for economic change (and other changes) after the United States' decade of descent that they not only blamed the Republican Party, they rejected anyone with even a hint of being a part of the economic policy mistakes, including Clinton.

Continue reading Is this the best time to commit new money to stocks?

Is this the best time to commit new money to stocks? originally appeared on BloggingStocks on Wed, 03 Dec 2008 12:45:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>Barack ObamaCongressdefense contractorsfeaturedfederal budgetfiscal stimulushealth carepharmaceutical sectorWed, 03 Dec 2008 12:45:00 EST<![CDATA[Celgene remains a top-tier biopharmaceutical]]>http://www.bloggingstocks.com/2008/04/29/celgene-remains-a-top-tier-biopharmaceutical/http://www.bloggingstocks.com/2008/04/29/celgene-remains-a-top-tier-biopharmaceutical/http://www.bloggingstocks.com/2008/04/29/celgene-remains-a-top-tier-biopharmaceutical/#commentsFiled under:

Readers of this space know that, for a plethora of reasons, companies in the pharmaceutical and biotech sectors are not my preferred stocks, but there are exceptions. And with the above in mind, Celgene is worth a review.

Celgene (NASDAQ: CELG) develops and markets drugs to treat cancer, immunological disorders and other diseases. The company's research concentrates on small molecule compounds that inhibit tumor necrosis factor alpha (TNFa) production or aberrant estrogen production, or that may regulate kinases and ligases (enzymes).

Analysts really like the revenue growth rate for Revlimid, which received U.S. FDA approval in 2005, and treats a malignant blood disease called MDS. In 2006, Revlimid also received FDA approval to treat myeloma. Total Revlimid revenue should exceed $1.7-$1.8 billion in 2008. Further, mainstay Thalomid, which treats bone marrow cancer, rounds-out an impressive one-two signature drug duo. Also, the near-term re-acquisition of European rights for Thalomid will expand Celgene's geographic footprint.

Continue reading Celgene remains a top-tier biopharmaceutical

Celgene remains a top-tier biopharmaceutical originally appeared on BloggingStocks on Tue, 29 Apr 2008 12:32:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>biotechcancercancer treatmentCelegeneCELGpharmaceutical sectorTue, 29 Apr 2008 12:32:00 EST<![CDATA[Celegene has a drug dynamic duo]]>http://www.bloggingstocks.com/2008/01/16/celegene-has-a-drug-dynamic-duo/http://www.bloggingstocks.com/2008/01/16/celegene-has-a-drug-dynamic-duo/http://www.bloggingstocks.com/2008/01/16/celegene-has-a-drug-dynamic-duo/#commentsFiled under:

In the current choppy/consolidating (or perhaps worse) market, pharmaceutical companies and selected biotechs garner attention as defensive plays, and among these Celgene is worth an evaluation.

Celgene Corporation (Nasdaq: CELG) develops and markets drugs to treat cancer, immunological disorders, and other diseases. The company's research concentrates on small molecule compounds that inhibit tumor necrosis factor alpha (TNFa) production or aberrant estrogen production, or that may regulate kinases and ligases (enzymes).

Analysts really like the revenue growth rate for Revlimid, which received U.S. FDA approval in 2005, and treats a malignant blood disease called MDS. In 2006, Revlimid also received FDA approval to treat myeloma. Mainstay Thalomid, which treats bone marrow cancer, rounds-out an impressive one-two signature drug duo.

Continue reading Celegene has a drug dynamic duo

Celegene has a drug dynamic duo originally appeared on BloggingStocks on Wed, 16 Jan 2008 18:43:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>biotech sectorcancercancer treatmentsCelegeneCELGhealth carepharmaceutical sectorWed, 16 Jan 2008 18:43:00 EST<![CDATA[Biomarin Pharma has what investors call a 'pipeline of significance']]>http://www.bloggingstocks.com/2008/01/11/biomarin-pharma-has-what-investors-call-a-pipeline-of-significa/http://www.bloggingstocks.com/2008/01/11/biomarin-pharma-has-what-investors-call-a-pipeline-of-significa/http://www.bloggingstocks.com/2008/01/11/biomarin-pharma-has-what-investors-call-a-pipeline-of-significa/#commentsFiled under: ,

Uncertain economic times, it goes without saying, create uphill conditions for most stocks. But that does not mean one should not search for promising opportunities, and one that fits the bill, for high-risk investors, is Biomarin Pharmaceutical.

Biomarin Pharmaceutical Inc. (Nasdaq: BMRN) develops and commercializes drugs for rare and chronic diseases.

Analysts like the fact that two of its drugs qualify for FDA orphan drug status, which grants exclusive marketing rights for seven years.

Biomarin's Aldurazyme, the sole therapy for mucopolysaccharidosis I (MPS I), obtained orphan drug status in the U.S. for seven years and in Europe for 10 years. Also, the company's Naglazyme is approved in the U.S. and Europe to treat MPS VI (Maroteaux-Lamy syndrome), another rare, genetic disease. The Reuters FY 2007/FY 2008 EPS consensus estimates for BMRN are -$0.15 to $0.49.

Continue reading Biomarin Pharma has what investors call a 'pipeline of significance'

Biomarin Pharma has what investors call a 'pipeline of significance' originally appeared on BloggingStocks on Fri, 11 Jan 2008 18:09:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>11108Biomarin PharmaceuticalBMRNdrugsFDAMPS IMPS VIorphan drugsPharmaceutical sectorU.S. Food and Drug AdministrationFri, 11 Jan 2008 18:09:00 EST<![CDATA[Onyx Pharmaceuticals is finding new ways to treat cancer]]>http://www.bloggingstocks.com/2008/01/04/onyx-pharmaceuticals-is-finding-new-ways-to-treat-cancer/http://www.bloggingstocks.com/2008/01/04/onyx-pharmaceuticals-is-finding-new-ways-to-treat-cancer/http://www.bloggingstocks.com/2008/01/04/onyx-pharmaceuticals-is-finding-new-ways-to-treat-cancer/#commentsFiled under:

The market's continued choppiness/consolidating pattern does not mean there aren't growth stocks out there for high-risk investors, and Onyx Pharmaceuticals is one pharmaceutical company that fits the bill.

Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) specializes in small molecule technology, a new, promising method that blocks cancer-causing mechanisms in the human body. In collaboration with Bayer Pharmaceuticals, the company develops and markets compounds that inhibit the function, or modulate the activity of the RAS signaling pathway to treat cancer and other diseases.

Analysts believe ONXX's cancer drug Nexaver as a treatment for advanced kidney cancer could be a big winner, with the company gaining FDA approval for the drug in 2005. ONXX is also testing the drug as a possible treatment for other kinds of cancer (liver, skin, and lung cancer). The Reuters F2007/F2008 EPS consensus estimates for ONXX are -$0.52 to $0.97.

Continue reading Onyx Pharmaceuticals is finding new ways to treat cancer

Onyx Pharmaceuticals is finding new ways to treat cancer originally appeared on BloggingStocks on Fri, 04 Jan 2008 18:39:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>cancercancer treamentshealth careONXXOnyx Pharmaceuticalspharmaceutical sectorFri, 04 Jan 2008 18:39:00 EST